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Abstract
Rheumatic diseases such as osteoarthritis (OA) are a major social and economic burden because of the 
population aging and the lack of curative solutions. An effective cell therapy may be the best treatment option 
for OA and other cartilage diseases. However, the main cellular strategy used to repair articular cartilage, the 
transplantation of autologous chondrocytes, is limited to a small number of patients with traumatic lesions. The 
use of joint replacement after years of disease progression proves the great medical need in current practice. 
Mesenchymal stromal/stem cells (MSCs) provide an alternative cell source for cartilage regeneration due 
to numerous advantages, comprising relative ease to isolate and culture, chondrogenic capacity, and anti-
inflammatory effects. Initial clinical trials with MSCs have led to encouraging results, but many variables have 
to be considered to attain true amelioration of disease or repair (type and status of cartilage disease, source 
and conditions of cells, administration regime, combinatorial approaches). Particularly, allogeneic MSCs are 
an advantageous cellular product. The animal models chosen for preclinical evaluation are also relevant for 
successful translation into clinical practice. Considering the limitations in the field, rigorous comparative 
and validating studies in well-established animal models (including large animals) are still needed to set up 
the bases for additional clinical trials. The present review of studies performed in small and large animal 
models should help clarify the applicability of MSC-based therapies for articular cartilage repair.
Keywords: Mesenchymal stromal cells, mesenchymal stem cells, cartilage repair, osteoarthritis, animal 
models, immune modulation.
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introduction
Human articular cartilage is affected by various 
rheumatic diseases, such as OA, and has a very 
limited capacity for regeneration. In Western 
countries, this type of diseases is a serious social 
and economic burden due to the aging population. 
Cell therapy is a promising treatment option for OA, 
but the high levels of inflammatory cytokines and 
other catabolic factors present in pathological joints 
may inhibit the synthesis of new articular cartilage 
or destroy newly formed articular cartilage (Lopes 
et al., 2017; Sommaggio et al., 2016). In addition, 
traumatic injury of cartilage, if not appropriately 
treated, leads to the early development of OA 
(Kwon et al., 2019). Currently, the transplantation 
of autologous chondrocytes extracted from low-
functional cartilage areas is the main cell therapy 
strategy used to regenerate cartilage, particularly 
for the filling of traumatic defects (Jones et al., 2019; 
Kwon et al., 2019). However, the extraction process 
is highly invasive and the expansion in culture of 
these cells leads to their dedifferentiation, negatively 
impacting upon the clinical outcome and limiting 
their applicability (Davies and Kuiper, 2019). In 
current practice, disease progresses in most cases, 
especially for OA patients. In this scenario, full joint 
replacement is conducted, providing evidence for 
the magnitude of the medical need. Furthermore, 
RA is also a pressing medical problem due to the 
limitations of current therapeutic options (Liu et al., 
2019). Although with lower incidence than OA, it is 
a complex cartilage disease with a more systemic 
profile and affecting a younger population. RA is also 
the object of intense study and could benefit from cell 
therapies with high immunoregulatory activity. In 
summary, many hurdles still need to be addressed 
for the successful application of cell therapies for 
articular cartilage repair.
 Rapid advances in the isolation of multipotent 
progenitor cells, routinely called MSCs, from 
various animal tissues and organs have been 
increasingly sought after for improving cellular 
therapies of cartilage repair (Afizah and Hui 2016). 
MSCs have shown good plasticity as they are able 
to differentiate towards multiple mesenchymal 
lineages, including chondrocytes, and have a proven 
anti-inflammatory effect (Ruiz et al., 2016). They lack 
the ethical complications of embryonic stem cells, 
are easy to isolate and expand in culture, and their 
collection is less damaging to the patient, allowing 
for the production of the necessary cells for therapy. 
Accordingly, MSCs are an attractive cell source 
for cartilage regeneration. Notably, MSCs are also 
being tested in combination with newly developed 
implantable scaffolds as a cell target/carrier for 
new therapeutic approaches (Kwon et al., 2019). 
Nevertheless, much more research is needed before 
feasible and widespread clinical application of MSCs 
becomes reality.
 Encouraging results have been obtained from 
the initial clinical trials with MSCs (Ruiz et al., 2016). 
However, many variables have to be considered in 
MSC-based therapy before it can become a well-
accepted and efficacious clinical practice. This 
includes the type and status of cartilage disease, cell 
source (tissue of origin, autologous or allogeneic) 
and dose, cell passage and culture conditions, genetic 
modifications, administration route/s, as well as 
timing and frequency of cell infusion (Afizah and 
Hui 2016). In this regard, the use of allogeneic MSCs 
is of special interest as it allows for the generation of 
a pre-tested and off-the-shelf product with multiple 
advantages over autologous cells. Specifically, it 
allows for the banking of MSCs obtained from healthy 
donors enabling quick availability and avoiding 
the delay inherent to autologous cell expansion. 
Furthermore, its usage would overcome limitations 
associated with obtaining autologous MSCs from 
elderly patients or with genetic or metabolic disorders 
(Chen and Tuan, 2008; Marycz et al., 2016).
 Choosing the right animal model/s for preclinical 
studies is also key for generating and extracting 
valuable information that allows establishing the 
therapeutic regimes (Lo Monaco et al., 2018). Small 
animal models have been used extensively for 
determining the behavior of MSCs under various 
conditions, but also pose many limitations. Rabbits, 
sheep and pigs are certainly of interest for studies 
of cartilage repair despite the higher cost; whereas 
horses could be considered to be both preclinical 
models, due to the similarity of equine and human 
cartilage (Ruiz et al., 2016), as well as potential 
beneficiaries of advanced cellular therapies owing to 
the high casualty of cartilage lesions in this species 
(Broeckx et al., 2019). Lastly, although restricted to 
a few studies in this area, the use of non-human 
primates is of very high preclinical value. The present 
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study reviews the knowledge and major advances 
been made at the preclinical level in the use of 
MSCs for articular cartilage repair in the mentioned 
species, with an emphasis on allogeneic MSCs. The 
information considered most valuable from each of 
these species was selected to cover all the spectrum 
of available tools. Particularly, studies in small 
animal models in the last years have focused on 
the optimization of the therapeutic conditions and 
generated encouraging results. Nevertheless, in most 
cases, subsequent confirmation in larger models and 
validation is still pending. Thus, additional work is 
needed at this level to continue progressing, with the 




The articular cartilage is a highly specialized tissue 
that lacks innervation and is avascular, obtaining 
nutrients by diffusion from the synovial fluid. It is 
formed mainly of water, different types of collagen 
(especially type II), proteoglycans and GAGs. 
Chondrocytes are the only cell type (showing a 
very low division frequency), represent 1-2 % of the 
tissue volume and secrete all the components of the 
ECM. ECM renewal is extremely slow. The ECM 
consists mainly of a dense net made of collagen 
fibers combined with macroaggregates of hydrophilic 
proteins loaded with water molecules. Cyclic 
pressures act on cartilage, mobilizing water molecules 
within the matrix. ECM stabilization depends on 
glycoproteins and proteoglycans, as well as integrins 
present on chondrocytes. With aging, cartilage 
suffers several changes, including reduction in the 
number of chondrocytes and quality and quantity 
of proteoglycans. Senescent cartilage behaves worse 
against mechanical requirements, which is a potential 
origin of pathologies such as OA, being the very-close 
relationships between cartilage aging and arthritis 
disease (Poole et al., 2001).
 Articular cartilage is organized into four different 
zones based on their functional and structural 
differences. The superficial zone lies next to the 
articular cavity and is in direct contact with the 
synovial fluid. Chondrocytes have a flattened 
morphology, produce thin horizontal collagen fibrils 
(Tallheden et al., 2006), and secrete lubricin to act as a 
lubricant in the joint (Flannery et al., 1999; Poole et al., 
2001). Just below, the medial zone, with more oval and 
larger chondrocytes, contains more proteoglycans 
and has a lower cell density. The collagen fibers are 
thicker and more randomly distributed. Next, there 
is the deep or radial zone, with fibers oriented more 
perpendicularly to the surface and the chondrocytes 
disposed into a column-like structure in parallel with 
the collagen fibers. Located below, the tidemark is a 
thin layer or interface that separates the non-calcified 
cartilage from the calcified zone. The chondrocytes 
in this last layer secrete type X collagen, a marker 
of hypertrophy responsible for the calcification of 
the ECM (Poole et al., 2001). Thus, this is a complex 
structure difficult to fully recover once it is lost.
Lesions and therapies
Cartilage integrity is essential for the proper function 
of the joint. The main problem is that, once injured, 
cartilage has a very low or even no repairing capacity. 
Most of the injuries are either due to mechanical 
trauma, also called focal lesion (very common in 
athletes), or to progressive degeneration, primary or 
secondary, as in the case of OA (Shi et al., 2017). OA 
is a multifactorial disease that leads to degradation 
of articular cartilage. Although the specific causes 
of the disease are still unknown, many risk factors 
have been identified, such as mechanical trauma, 
age, obesity, diabetes, inflammation, and genetics. 
After cartilage degradation, the subchondral bone 
gets exposed resulting in stiffness, inflammation, and 
pain (Alfredson et al., 1999; Lorentzon et al., 1998).
 Inflammation itself is the cause of many of the 
symptoms. In pathological conditions, chondrocytes 
secrete a variety of inflammatory mediators such 
as proteases (collagenases, aggrecanases, etc.), 
pro-inflammatory cytokines (IL-1α, IL-1β, TNFα, 
IL-8, IL-17, IL-18), anti-inflammatory cytokines and 
antagonists (IL-4, IL-10, IL-13, IGFs, MCP-1, TGF-β, 
NO) etc. (Hunziker et al., 2002; O’Hara et al., 1990). 
Pieces of degraded cartilage are phagocyted by 
synovial cells, which also secrete pro-inflammatory 
mediators, leading to secretion of proteolytic enzymes 
and further cartilage degradation. This response 
is amplified by B cells, T cells and macrophages. 
Complement activation also plays a role in this 
process, contributing to cartilage inflammation, 
degradation, and OA (Sommaggio et al., 2013; Wang et 
al., 2011). On the other hand, the synovial membrane 
contributes to bone spur formation through BMP 
signaling (Sellam et al., 2010).
 The goal of cartilage repair is to reconstitute the 
lesion with a tissue that has identical or at least very 
similar properties to the original cartilage, including 
integration into surrounding tissue. To date, there is 
no treatment that fulfils these requirements, although 
some therapies improve the patients’ experience. 
Non-surgical treatments of the symptoms include 
standard analgesic and anti-inflammatory treatments 
(Vista et al., 2011), as well as dietary supplements 
such as chondroitin sulfate. The most common 
surgical treatment is the total joint replacement 
by means of a prosthesis once the function is lost 
or pain is unbearable. However, other methods, 
such as debridement (Moseley et al., 2002) or 
osteochondral auto and allograft (McCoy and Miniaci 
et al., 2012), have been used. Regarding cell-based 
treatments, autologous chondrocyte implantation 
(used either alone or in combination with scaffolds) 
is the approach clinically approved for the filling 
of chondral defects and is considered to produce 
the best outcomes (Davies and Kuiper 2019; Riboh 
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et al., 2017; Shanmugaraj et al., 2019). Furthermore, 
chondrocytes are also of interest for the development 
of cell therapies for OA (Cherian et al., 2015; Sato et 
al., 2019; Schinhan et al., 2013). The use of multipotent 
or stem cells is a promising way to eliminate the 
need for a cartilage biopsy and an attractive choice 
for targeting cartilage diseases with an inflammatory 
component such as OA and RA. In the case of MSCs, 
the results are promising, but superiority to other 
treatments in animal studies is not consistent (Dahlin 
et al., 2014; Kwon et al., 2019, Liu et al., 2019; Xing et 
al., 2018). Thus, more stringently designed studies are 
needed, first at the preclinical and then at the clinical 
level to show significant improvement or at least 
non-inferiority. A scheme of OA, therapeutic targets, 
current treatments, and therapies in development is 
shown in Fig. 1.
MsCs
According to the standard definition of MSCs by the 
ISCT (Dominici et al., 2006), these clonal cells adhere 
to plastic, express CD markers such as CD73, CD90, 
and CD105, and can differentiate into adipogenic, 
chondrogenic, and osteogenic lineages in vitro. 
Particularly, these multipotent fibroblast-like cells can 
be found in almost all tissues and can differentiate 
towards bone (Tawonsawatruk et al., 2012), cartilage 
(Yeh et al., 2013), muscle (Park et al., 2016), tendon, 
ligament (Liang et al., 2013), fat (Contador et al., 
2015), and a variety of other connective tissues (Kil 
et al., 2016; Ullah et al., 2016) (Fig. 2). MSCs display 
high self-renewal capacity, a process by which a 
stem cell divides asymmetrically or symmetrically 
forming one or two daughter stem cells with a similar 
potential to the mother cell (Wang et al., 2013), while, 
simultaneously, maintaining pluripotency (Jiang et 
al., 2002). However, isolated MSCs have been reported 
to vary in their potency and self-renewal potential. As 
a result, the MSCs used for clinical applications often 
lead to variable or even conflicting results.
 MSCs have been isolated from many different 
adult tissues, including bone marrow (Karaoz et al., 
2009), adipose tissue (Blazquez-Martinez et al., 2014), 
synovial membrane (De Bari et al., 2001), connective 
tissues of dermis (Manini et al., 2011), skeletal 
muscle (Almeida and O’Brien, 2013), peripheral 
blood (Trivanović et al., 2013), liver (D’souza et al., 
2015), lung (Gong et al., 2014), blood vessels (Pacini 
and Petrini, 2014) as well as from rather “young 
sources” such as amniotic fluid (Pappa and Anagnou, 
2009), amniotic membrane (Díaz-Prado et al., 2011), 
umbilical cord blood (Secco et al., 2008), umbilical cord 
stroma (Fernández-Pernas et al., 2016), or placenta 
(Pelekanos et al., 2016). In recent years, the number 
of tissues with a potential for tissue engineering has 
increased (Rossignoli et al., 2013). Notably, MSCs 
can differentiate both in vivo and in vitro into various 
mesenchymal cells and exhibit remarkable plasticity, 
given their ability to trans-differentiate towards 
different lineages (Jeon et al., 2016; Jin et al., 2013). 
However, only a small percentage of the injected 
MSCs differentiate and migrate in vivo, which would 
not justify the therapeutic effects observed (Murphy 
et al., 2003). The focus on MSC therapeutic ability is 
currently being moved to their regulatory properties, 
since MSCs can interact with their environment and 
elicit trophic, proangiogenic, and anti-inflammatory 
effects. By cross-talking with immune cells by both 
direct cell-cell contact and paracrine signaling, MSCs 
promote regulation of the catabolic environment 
of the diseased joint. This paradigm shift is highly 
relevant, meaning that MSCs would not only be 
‘building blocks’ but actually have the ability to direct 
the healing process (Barry and Murphy, 2013).
fig. 1. scheme of oA with potential therapeutic targets, current and future therapies. Both physiological 
and immunological alterations should be addressed for the development of a successful and efficacious OA 
therapy. Renewal of the cellular and ECM compartments is needed for the formation of high-quality hyaline 
cartilage at the proper anatomical site and full functional recovery.
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Paracrine effects and immunomodulation
MSCs have the capacity to secrete a wide variety of 
cytokines, chemokines, and growth factors. Several 
studies based on examination and modulation of the 
MSC secretome in vivo have identified high levels 
of proteins involved in the immune response such 
as IL-6, IL-8, MCP-1, and TGF-β; ECM remodelers 
such as TIMP-2, fibronectin, periostin, collagen, 
decorin, and metalloproteinase inhibitors; growth 
factors and their regulators such as VEGF, CM-CSF, 
BMP-2, bFGF, as well as IGFBP3, 4, and 7 (Elahi 
et al., 2016) (Fig. 2). Notably, the MSC secretome, 
either directly or through extracellular vesicles, 
influences cartilage regeneration, especially by the 
release of TGF-β-superfamily proteins (Lo Monaco 
et al., 2018). This process contributes to cartilage 
repair mostly by stimulating endogenous cells and 
promoting the deposition of collagen type II and 
glycosaminoglycans (Murphy et al., 2003; Zhang et 
al., 2016).
 MSCs can modulate the immune system and 
are effective for the treatment of various immune 
response disorders in both human and animal models 
(de Miguel-Beriain et al., 2015; Jung et al., 2012; Li et 
al., 2009). The underlying mechanism of immune 
modulation is not fully understood. However, there is 
evidence for both cell-to-cell contact mechanisms and 
release of soluble immunosuppressive factors. They 
interact with a broad range of immune cells and avert 
the excessive response of T and B cells, dendritic cells, 
macrophages, and natural killer cells (Chao et al., 2008; 
Jung et al., 2012). Furthermore, MSCs can also induce 
regulatory T cells and maintain their suppressive 
activity on self-reactive T-effector responses (Chen et 
al., 2004). In recent years, it was proposed that MSCs 
interact with their environments both by negatively 
regulating the immune response, in case of major 
inflammation, or stimulating the immune response 
system by releasing pro-inflammatory molecules 
when the level of inflammatory cytokines is low 
(Marquina et al., 2017).
 Regarding their migratory capacity, MSCs have 
been reported to reach damaged tissue in response 
to a combination of signaling molecules coming 
from the injured tissue. Homing-related molecules 
in general can be up-regulated by inflammatory 
fig.2. MsC secretome. Representation depicting a typical MSC from a mesoderm lineage (bone, umbilical 
cord, adipocyte tissue or muscle) with its surface markers attached to its plasma membrane (CD73, CD90, 
CD105) and surrounded by its secretome. The secretome is made up of proteins involved in the immune 
response (IL-6, IL-8, MCP-1, TGF-β, TIMP-2, VEGF, CM-CSF, BMP-2, bFGF, IGFBP3, IGFBP4, IGFBP7), which 
confers its paracrine properties to these cells.
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cytokines such as TNFα and IL-1 (Tanaka, 2015), 
suggesting that different inflammation states might 
promote distinct MSC engraftment and therapeutic 
efficiencies (Chen and Tuan, 2008). Particularly, 
expression of hyaluronic acid and its receptor CD44 
by MSCs may be involved in the migration of MSCs 
to cartilage defects (Lo Monaco et al., 2018).
preclinical studies of articular cartilage repair by 
MsCs
In agreement with the progress of advanced 
therapies for cartilage repair, an effort has been 
made during the last decade towards the preclinical 
assessment of MSC-based therapies. This research 
has involved a wide variety of animal models, 
comprising both small and large animals, multiple 
disease indications and procedures (i.e. traumatic 
injury of various joints, induced or spontaneous 
OA, and RA), as well as different MSC origins and 
administration regimes (Table 1-3). The large amount 
of information available, sometimes contradictory, 
justifies a thorough appraisal of this topic. Notably, 
an extensive review of the factors under consideration 
for choosing one or another species has been recently 
conducted (Lo Monaco et al., 2018).
 Interest in MSCs for treating joint injuries was 
firstly raised because of the differentiation ability of 
these cells, assuming that MSCs would differentiate 
into chondrocytes to replace the damaged articular 
cartilage. Nevertheless, their regulatory features are 
now receiving more attention as these might be key 
for providing clinical benefit. The ability of MSCs 
to inhibit proliferation and regulate function of 
different immune cells in vitro has been demonstrated 
in different species (Carrade et al., 2013). Notably, 
variations in the immunomodulatory capacity of 
MSCs from the different species as compared to 
human MSCs should also be considered (Carrade 
and Borjesson 2013; Su et al., 2014). In general, large 
animals, being more similar to humans, provide 
higher value for preclinical studies, but their use is 
more costly and restricted.
 Mediators secreted by MSCs also vary between 
tissue sources (Carrade et al., 2013), influencing their 
immunoregulatory activities and therapeutic efficacy. 
Recent experience in horses could provide relevant 
information in this respect. Equine MSCs from a 
hematic source produce NO but MSCs from solid 
tissues do not (Carrade et al., 2013). It is not clear to 
what extent the differences among secretory profiles 
in vitro may influence the MSC therapeutic efficacy 
in vivo. Nevertheless, it might explain the improved 
healing observed in tendinopathies treated with 
UC-MSCs and BM-MSCs that displayed superiority 
over AT-MSCs (Carrade et al., 2013; Romero et al., 
2017). Some molecules, such as IDO and iNOS, are 
not expressed or secreted in basal conditions but are 
activated upon inflammatory stimulation (Barrachina 
et al., 2017), whereas other mediators such as TGF-β1 
and HGF are constitutively produced (Barrachina 
et al., 2016; Carrade et al., 2012; De Schauwer et al., 
2014). Since inflammatory priming may be needed 
to induce MSC full regulatory function, stimulating 
MSCs with proinflammatory cytokines prior to in vivo 
administration is an interesting strategy to improve 
their therapeutic potential (Cuerquis et al., 2014).
 Both autologous and allogeneic cells display 
similar immunomodulatory properties (Colbath 
et al., 2017b; Ranera et al., 2016) and, thus, would 
be equally able to modulate inflammation in joint 
pathologies. However, concerns are rising about 
the immunogenicity of allogeneic MSCs. Thus, an 
additional highly relevant paradigm change is the 
concept that MSCs are not truly immune-privileged 
but immune-evasive (Ankrum et al., 2014) (Fig. 3). In 
fact, the expression level of MHC-I and II molecules 
in MSCs is not static but regulated by conditions 
such as inflammation (Barrachina et al., 2017; Chan 
et al., 2008) and differentiation (Barrachina et al., 
2018a; Lohan et al., 2014) (Fig. 3b). In addition, MHC 
matching between donor and receptor probably 
determines the production of cellular and humoral 
immune responses (Barrachina et al., 2020; Beggs et 
al., 2006; Berglund et al., 2017; Pezzanite et al., 2015; 
Poncelet et al., 2007), potentially limiting the repeated 
administration of allogeneic MSCs (Fig. 3a).
 Repetitive MSC administration has been 
suggested to improve their therapeutic potential 
in joint pathologies (Hatsushika et al., 2014) since 
their lifespan in vivo appears to be short, especially 
for the allogeneic ones (Ryan et al., 2014). However, 
allogeneic studies are mainly focused on single 
administration, especially in large-animal models. 
In these models, repeated administration has been 
studied in healthy joints as proof of concept for 
their safety, but few studies have used repeated i.a. 
administration of allogeneic MSCs in pathological 
joints (Barrachina et al., 2018b; Magri et al., 2019). 
So far, single or repeated i.a. administration of 
allogeneic MSCs has been shown to be safe, although 
a slight-to-mild transient inflammatory reaction is 
occasionally observed (Ardanaz et al., 2016; Broeckx 
et al., 2014b). However, this type of response has 
also been found when using autologous cells and 
it has been hypothesized to be due to the high 
sensitivity of the joint or because potential FBS 
xeno-contamination (Ardanaz et al., 2016; Carrade 
et al., 2011; Pigott et al., 2013a; Pigott et al., 2013b). 
Therefore, a potential xenogeneic response raised by 
bovine proteins used for culture supplementation is 
another variable to account for in preclinical models 
on the way to develop safe treatments (Joswig et al., 
2017). Alternatives, such as platelet lysate, are thus 
being investigated (Iudicone et al., 2014).
 Future studies are needed to clarify the implications 
of both immunomodulation and immunogenicity in 
therapy with MSCs to treat joint pathologies. How 
these factors affect their chondrogenic capacity is also 
highly relevant, but this question remains mainly 
unanswered.
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fig. 3. immune recognition of MsCs. (a) Schematic representation of how MSCs can be directly or indirectly 
recognized and develop both cellular and humoral immune responses, thus potentially leading to immune 
memory that would limit repeated administration. (b) Summary of current knowledge regarding the different 
factors affecting the balance between immunogenicity and immunomodulation of MSCs and thus, their 
immune evasive ability. Up and down arrows represent increase and decrease, respectively; equal symbol: 
no relevant change. 
a
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preclinical studies assessing the repair of 
traumatic cartilage defects by MsCs
Most studies of defect cartilage repair are focused 
on assessing benefit by quantity and quality 
determinations of the generated tissue (Table 1). 
Therefore, these studies assess the chondrogenic 
effects, either direct or indirect, of MSCs in small- and 
large-animal models.
 Rats and rabbits have both been used for studying 
the use of MSCs for treating different cartilage 
defects. Particularly, rats have been used as models 
for the repair of osteochondral and meniscal defects 
(Table 1). However, only Okuno et al. (2014) have 
studied the use of allogeneic rat MSCs for these 
models, pointing out a constraint of this research 
line. Notably, most of these rat studies assess the 
effect of human MSCs (Horie et al., 2012; Kohli et 
al., 2019; Park et al., 2019), and a few use syngeneic 
rat MSCs (Yamaguchi et al., 2016; Yin et al., 2016). 
Interestingly, syngeneic and minor-mismatched 
synovial MSCs promote better repair than MSCs 
with a major mismatch in a rat model of meniscus 
regeneration (Okuno et al., 2014). Although MSC 
administration is always directed to the joint for 
this set of studies, there are relevant variations in 
form, as some involve single i.a. injections, others 
the combination with hydrogels, and still others use 
MSC aggregates with or without biomaterials. The 
outcomes are also diverse in terms of generation 
of hyaline cartilage (Kohli et al., 2019; Park et al., 
2019), but most report some degree of improvement 
(Horie et al., 2012; Park et al., 2019; Yamaguchi et al., 
2016; Yin et al., 2016). In fact, Park et al. (2019) have 
found that undifferentiated MSCs produce better 
cartilage than chondrogenic-pre-differentiated MSCs. 
Nevertheless, a direct comparison of chondrocytes 
and MSCs in their capacity to generate hyaline 
cartilage in an osteochondral defect in rat shows 
the superiority of chondrocytes (Dahlin et al., 
2014). There is some controversy on this topic, 
but these findings are in keeping with the current 
clinical situation (Kwon et al., 2019). Furthermore, 
isolated and cultured chondrocytes also display 
immunoregulatory capabilities (Lohan et al., 2016). 
With these considerations, cellular therapies 
for cartilage repair based on the implantation 
of genetically modified porcine chondrocytes 
(potentially available in large amounts) are also 
in development (Costa et al., 2003; Marquina et al., 
2017; Sommaggio et al., 2016). The interest in MSCs 
mainly relies on exploiting their immunoregulatory 
activity in combinatorial approaches with xenogeneic 
chondrocytes. Unmodified porcine chondrocytes 
injected into the rat joint trigger xenogeneic cellular 
and humoral immune responses. Accordingly, 
the immune effect of systemic administration of 
allogeneic MSCs (derived from bone marrow) has 
been initially assessed in this rat model (Marquina 
et al., 2017). No antibody response against MSCs was 
found after a single MSC injection, but the regime 
used did not reduce the immune response against 
non-transgenic chondrocytes (Marquina et al., 2017). 
In fact, i.v. administration of MSCs one week prior 
to chondrocyte i.a. injection was proinflammatory 
and enhanced the xenogeneic immune response. 
Thus, further studies are needed to assess additional 
protocols if MSC-mediated protective conditions are 
sought. Notably, this is still a requirement when the 
goal is cartilage regeneration.
 There is a very large body of work on studying 
repair of cartilage defects of the joint in rabbits, 
also involving various models (chondral and 
osteochondral defects, meniscal lesions), scaffolds, 
and types of MSCs (Table 1). Most of these studies use 
rabbit MSCs from the same strain/breed and should 
be considered to be syngeneic or possibly with minor 
mismatches depending on the level of inbreeding 
(Cipriani et al., 2019; Guo et al., 2018; Shimomura et 
al., 2014; Shimomura et al., 2019; Tatebe et al., 2005; 
Xia et al., 2018). Overall, this intense research, with 
a focus on structural reconstruction, has produced 
encouraging results through multiple strategies 
based on advanced scaffolds. Likewise, the few 
studies testing human MSCs in rabbit models also 
reported good outcomes (Jang et al., 2014; Pescador 
et al., 2017). Notably, recent work indicates that MSCs 
could be better for regenerating bone than cartilage 
in an osteochondral defect (Cipriani et al., 2019), 
encouraging the development of bilayer systems. 
Furthermore, the generation of high-quality hyaline 
cartilage with zonal distributions has been recently 
described using procedures based on this type of 
approach. Particularly, Wu et al. (2020) observed 
that implantation of nanopatterned differentiated 
MSCs within a stratified bilayered hydrogel construct 
improved the repair quality of cartilage defects as 
determined by histological scoring, mechanical 
properties, and polarized microscopy analyses.
 The use of allogeneic MSCs for this type of studies 
is infrequent. Nevertheless, Mahmoud et al. (2018) 
have recently shown that rabbit allogeneic MSCs are 
equally effective when compared to autologous MSCs 
in repairing an osteochondral defect. Furthermore, 
the study demonstrated that co-culturing different 
types of MSCs leads to the generation of better-
quality hyaline cartilage and subchondral-bone 
repair (Mahmoud et al., 2019a). Even so, caution 
should be taken regarding the translation of these 
results into the clinical setting as allogenicity may 
have a higher impact in humans. Interestingly, the 
immunological properties of allogeneic MSCs are 
probably influenced by the type of scaffold used 
(Yuan et al., 2011) and this is an additional factor that 
should be considered for future studies to ensure 
proper development for clinical trials. Overall, 
further studies in high-valued preclinical animal 
models may be advised to validate those results and 
progress towards clinical applications, particularly 
for allogeneic cell-based products.
 The efficacy of MSCs for the repair of articular 
chondral defects in large-animal studies has 
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been mainly assessed in sheep using autologous 
cells, leading to variable outcomes (Table 1). The 
approaches tested comprise either i.a. injection of 
MSCs or MSCs combined with hydrogels or scaffolds 
placed into the generated defect (Music et al., 2018). 
In general, more work is needed to establish the most 
favorable conditions that lead to hyaline cartilage 
regeneration in this species. Interestingly, Guillén-
García et al. (2014) have shown in the ovine model 
that autologous chondrocytes seeded at high density 
lead to a better cartilage repair than using the same 
amount of autologous MSCs. Autologous MSCs 
have also been investigated for the treatment of focal 
chondral defects in horses (Table 1). These have been 
conducted almost exclusively in combination with 
different types of scaffolds (Gonzalez-Fernandez et al., 
2016; Goodrich et al., 2016; Seo et al., 2013; Wilke et al., 
2007) or as a complementary treatment after surgery 
(Ferris et al., 2014; McIlwraith et al., 2011). Since the 
present review seeks to emphasize the advances 
been made with allogeneic cells, these studies will 
not be discussed extensively. Nevertheless, it is 
worth mentioning that promising results have been 
observed, even though the heterogeneity in scaffold 
materials and study designs hampers extracting 
definitive conclusions (Colbath et al., 2017a).
 Despite promising results, the integration of 
repaired cartilage with the surrounding native 
cartilage remains a major challenge for tissue-
engineering strategies of cartilage repair. In this 
regard, an independent investigation focused on 
the incorporation of MSCs into gels to improve 
the integration and repair of cartilage defects 
using a cynomolgus macaque model with a full-
thickness cartilage defect. The transplantation 
of autologous MSCs in a collagen gel produced 
a better-quality cartilage, with a regular surface 
and seamless integration with neighboring native 
cartilage, relative to using gel alone (Araki et al., 
2015). More recently, Kondo et al. (2017) investigated 
whether transplantation of aggregates of autologous 
synovial MSCs promotes meniscal regeneration 
in aged primates, as the anatomy and biological 
properties of the meniscus depend on animal 
species. They concluded that transplantation of 
aggregates of autologous synovial MSCs promotes 
meniscus regeneration and delays progression of 
articular cartilage degeneration in aged primates. 
This work constitutes the first report dealing with 
meniscus regeneration in primates (Kondo et al., 
2017). Unfortunately, no studies using allogeneic 
MSCs from non-human primates are available for 
comparison.
 The chondrogenic potential of allogeneic MSCs 
obtained from large animals has been mainly studied 
in pig models of articular cartilage repair (Table 1) 
(Fisher 2016; Hatsushika et al., 2014; Nakamura et al., 
2012). Although there are also variations in the degree 
of success, the best results have been obtained using 
synovial MSCs for either filling of cartilage defects 
(Nakamura et al., 2012) or meniscus regeneration 
through repeated i.a. injections (Hatsushika et al., 
2014). Regarding the use of allogeneic MSCs for 
cartilage regeneration in sheep, this approach has 
been only used for the repair of lumbar intervertebral 
discs, with encouraging results (Freeman et al., 2016; 
Oheme et al., 2016). Occasionally, human MSCs 
have been used in these large-animal models. As 
in small-animal models, the fact that these cells are 
xenogeneic for these combinations did not seem to 
impact negatively upon efficacy (Hopper et al., 2015; 
Li et al., 2009b). Thus, these preclinical models seem 
appropriate under the current level of knowledge 
for the validation and safety analyses of human MSC 
preparations intended for clinical trials. Notably, 
no comparative studies are available that establish 
whether autologous MSCs provide superior benefit 
relative to allogeneic and human MSCs in these large-
animal models.
 In summary, the use of allogeneic MSCs is gaining 
attention, but it is still rarely utilized in preclinical 
studies of osteochondral repair and especially in 
large-animal models. Accordingly, the implications 
of their use relative to autologous MSCs are not yet 
well established. Furthermore, it is still likely that 
chondrocytes represent a better cell type for the 
generation of high-quality hyaline cartilage. Thus, 
strategies that combine MSCs and chondrocytes 
(Nazempour and Van Wie, 2016) are also of great 
interest.
preclinical studies assessing MsC-based 
therapies for oA
The effect of MSCs on the treatment of OA is 
dual, comprising both the chondrogenic and 
immunoregulatory activities, in accordance with 
the complex pathogenesis of OA. To assess their 
therapeutic efficacy, there is a wide variety of OA 
animal models generated using different species 
and approaches and each studying MSCs with 
different origins and administration regimes (Table 
2). Despite their small size, mice have been used for 
OA modeling, mostly following the collagenase-
induced OA model (Table 2). In keeping with the 
encouraging results obtained in this model, the 
efforts have been mostly focused on studying human 
MSCs for developing MSC-based therapies based 
on i.a. administration (Maumus et al., 2017; Morille 
et al., 2016). Although the molecular mechanisms 
of protection are not fully elucidated, the anti-
inflammatory and anti-catabolic effects exerted by the 
MSC secretome seem to play a major role (Cosenza 
et al., 2017; Maumus et al., 2017). Nevertheless, these 
findings lead to the consideration of other related 
strategies for therapeutic intervention such as the 
direct use of exosomes and/or microparticles obtained 
from MSCs (Cosenza et al., 2017), or even injection 
of MSC secretome (Khatab et al., 2018). Regarding 
the use of allogeneic MSCs in this model, only one 
report describes the use of allogeneic MSCs (an MSC 
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cell line) in an OA mouse model (Xia et al., 2015). 
Interestingly, it showed that i.a.-injected MSCs 
genetically modified to produce a TNF-blocking 
molecule provide further protection from disease 
progression (Xia et al., 2015).
 Various approaches have been used for OA 
modeling in rats. More often, an i.a. injection of MIA 
has been applied to rats to induce an arthritis model 
– considered an OA model by most groups (although 
occasionally reported as an RA model). The results 
generated in the MIA-induced arthritis and other rat 
OA models (Table 2) do not always support a potential 
beneficial effect of MSC administration (Neybecker et 
al., 2018; van Buul et al., 2014). For this reason, efforts 
have been recently focused on improving protocols 
(usually i.a.-based) and efficacy through various 
strategies such as combination with chondrocytes 
(Ahmed et al., 2014), repetitive MSC administration 
(Ozeki et al., 2016), combination with small drugs 
and administration routes (Lee et al., 2018), or early 
intervention (Sakamoto et al., 2019). Much of this 
preclinical work has been conducted in a xenogeneic 
setting, using human MSCs for determining their 
therapeutic potential (Lee et al., 2018; Neybecker et 
al., 2018; Ozeki et al., 2016). In fact, only two teams 
have used allogeneic MSCs in this setting (Mei et al., 
2017; Yang et al., 2015). Interestingly, a beneficial effect 
of a single i.a. administration of allogeneic MSCs 
has been reported in the rat OA model generated 
by ACLT (Mei et al., 2017). Overall, the information 
regarding the immunoregulatory properties of MSCs 
in this setting is very limited. Nevertheless, there 
are indications that benefit might be associated with 
diminished pro-inflammatory cytokines in the joint 
(Lee et al., 2018; Sakamoto et al., 2019).
 Multiple teams have contributed to this research 
topic using different OA rabbit models and types of 
MSCs (including two studies with allogeneic MSCs) 
(Table 2) (Chiang et al., 2016; Hermeto et al., 2016; 
Mahmoud et al., 2019b; Saulnier et al., 2015; Singh et 
al., 2014), adding an additional level of complexity. 
Nevertheless, the i.a. route has been favored for 
all these studies, obtaining generally beneficial 
effects and preventing disease progression when 
optimizing the conditions of MSC usage. Thus, an 
early intervention with MSCs is more protective 
than a late MSC administration (Saulnier et al., 2015). 
Moreover, repeated MSC injections work better than 
a single MSC administration (Mahmoud et al., 2019b). 
Notably, allogeneic MSCs were highly efficacious, 
although no direct comparison with the autologous 
or syngeneic cells was conducted in this setting .
 Regarding studies in large animals, sheep have 
been used as OA models for assessing MSC-based 
therapies as reviewed by Music et al. (2018), although 
with mixed results (Table 2). Likewise, no consistency 
has been observed for the provided benefit in the 
two OA studies reported in pigs (Table 2). In a 
well-defined OA model, Xia et al. (2018b) found no 
difference in BM-MSC-treated lesions relative to 
controls. However, it is unclear whether the labelling 
of the MSCs with magnetic nanoparticles affect their 
protective functions (Xia et al., 2018b). In contrast, Wu 
et al. (2019) observed improved cartilage repair at both 
macroscopic and histological levels after two pigs 
were subjected to a complex surgical intervention of 
cartilage injury followed by transplantation with UC-
MSCs in hyaluronic acid. Regarding dogs, these are 
also used to some degree for studying the therapeutic 
potential of MSCs (Harman et al., 2016). However, 
their relevance as a preclinical model for humans is 
hampered by the very different cartilage load and 
features and its value should be based on assessing 
mainly the MSC immunomodulatory effects (Table 
2). Thus, no conclusions can be extracted at this stage 
with the limited amount of information available.
 Although limited, there is a larger number 
of studies investigating the use of MSCs as OA 
treatment in horses (Table 2). However, the results 
are less conclusive than for cartilage repair in this 
species. Autologous BM-MSCs have not led to a 
significant improvement in a post-traumatic OA 
experimental model, except for a reduction in the 
synovial concentration of PGE2 (Frisbie et al., 2009). 
Nevertheless, in a chemically induced OA model, 
equine autologous MSCs did show beneficial 
effects on cartilage repair, especially in the short-
term and after early cell administration (Mokbel 
et al., 2011). Different results between studies may 
be related to the more severe inflammation in the 
chemically-induced model (Colbath et al., 2017a), 
since increased MSC effectivity under inflammatory 
situation has been described both in vitro and 
in vivo in other species (Manferdini et al., 2013; 
Schelbergen et al., 2014). The use of allogeneic MSCs 
in equine joint pathologies is increasingly being 
investigated, but several knowledge gaps still exist. 
In a model of acute synovitis, allogeneic MSCs 
reduced the nucleated cells and neutrophil counts 
in synovial fluid (Williams et al., 2016). In naturally 
occurring OA, allogeneic MSCs undifferentiated 
or chondrogenically pre-differentiated showed 
increased beneficial effects when combined with PRP, 
especially the pre-differentiated ones, both in a short 
(6 week) and long term (12 months) (Broeckx et al., 
2014a). Promising results have also been shown by 
using allogeneic undifferentiated or chondrogenically 
induced MSCs with no other orthobiological 
combination, the second ones reaching higher 
percentage of animals returning to their previous 
training level. Furthermore, it is remarkable that 
only 3 out of 165 treated horses developed a flare 
reaction after i.a. administration of allogeneic cells 
(Broeckx et al., 2014b). Recently, the same research 
group conducted a randomized, double-blinded, and 
placebo-controlled study enrolling 75 horses with 
early OA to assess single administration of allogeneic 
chondrogenically induced MSCs. Animals receiving 
these MSCs showed significant clinical improvement 
in the short term (week 3 to 18 post-treatment) when 
compared to the placebo group. At longer term (1 
year), a significantly larger number of horses in the 
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treated group returned to their previous work level. 
Importantly, no relevant side effects were noticed 
(Broeckx et al., 2019). Similar results regarding clinical 
benefit were obtained in a recent study that compared 
single and repeated administration of allogeneic UC-
MSCs in naturally occurring OA (Magri et al., 2019). 
However, a second administration of MSCs did not 
provide additional benefit.
 Repeated allogeneic i.a. administration in equine 
pathological joints has also been investigated together 
with the effect of priming the cells in vitro with 
TNFα and IFNγ to induce their immune regulatory 
potential prior to administration, a suggested 
strategy commented above (Barrachina et al., 2018b). 
Clinical and synovial inflammatory signs were 
reduced faster in both (unstimulated and primed) 
MSC-treated groups when compared to untreated 
controls, and repeated allogeneic administration 
did not produce adverse reactions. However, only 
animals receiving primed MSCs showed a slight and 
transient local inflammatory reaction after the second 
injection, which might have resulted from increased 
immunogenicity of primed cells. Both MSC-treated 
groups showed enhanced cartilage gross appearance 
at short- (2 months) compared to long-term (6 months) 
evaluations and histochemistry suggested delayed 
progression of proteoglycan loss in MSC-treated 
groups (Barrachina et al., 2018b). The gene expression 
of several markers in cartilage and synovium revealed 
a stronger anti-inflammatory effect of primed MSCs, 
especially at short term (Barrachina et al., 2018b). 
Similarly, xenogeneic administration of equine MSCs 
showed that MSCs pre-stimulated with IFNγ elicited 
higher chondroprotective potential when compared 
to unstimulated MSCs in a mouse model of joint 
pathology (Maumus et al., 2016). Another xenogeneic 
study (horse-to-rabbit model) further highlighted 
the importance of an early treatment and suggested 
that the main target of MSCs inside the joint is the 
synovium, since these cells are able to diminish the 
expression of degradative enzymes and inflammatory 
mediators, thus promoting an anti-catabolic joint 
environment (Saulnier et al., 2015). Interestingly, a 
recent work with allogeneic MSCs selected for high 
integrin expression in order to target the cells to the 
cartilage lesion, also produced encouraging results in 
a novel post-traumatic OA model (Delco et al., 2020). 
In summary, the study of allogeneic MSCs in equine 
joints is more limited than for autologous MSCs and 
mostly focused on OA. Allogeneic administration 
appears to be safe and effective, and efficacy seems to 
be mainly associated with MSC immunomodulatory 
properties. The apparently short effect of allogeneic 
MSC in vivo may be improved by repeating the 
administration, but concerns are raised regarding 
immune memory development.
 In spite of their similarity to humans, non-human 
primates are complex models for assessing MSC 
therapeutic potential in OA (Table 2). A cynomogus 
monkey (Macaca fascicularis) model of OA was 
established by Ham et al. (2002). This animal model 
was initially used to assess the efficacy of different 
hormone treatments for OA (Ham et al., 2004; Olson 
et al., 2007). More recently, Fernández-Pernas et al. 
(2017) have demonstrated in an OA model generated 
by creating a lesion in the knee articular cartilage that 
MSCs isolated from human synovial membranes 
are recruited into the injured joint after intravenous 
injection. Furthermore, MSCs injected into the 
injured defect of the joint stay there, although a 
small percentage migrates out of the knee over time. 
Interestingly, native cells positive for MSC markers 
are also mobilized in the injured joint towards the 
defect independently of the MSCs injected for the 
lesion repair (Fernández-Pernas et al., 2017). In 
non-human primates, the efficacy of cartilage repair 
by MSCs was initially assessed in a collagenase-
induced OA model (Jiang et al., 2014). The articular 
cartilage lesions in cynomolgus monkey were 
treated locally with autologous polyclonal MSCs, 
a selected population of chondrogenic MSCs, or 
normal saline as control, and followed for 8, 16 and 
24 weeks. A significant improvement was observed 
after evaluation of the cartilage repair by clinical, 
radiographic, and histological examinations in the 
cohorts treated with MSCs, particularly in the group 
treated with the selected chondrogenic clonal MSCs 
(Jiang et al., 2014).
 There are no studies in non-human primates that 
assess the efficacy of well-characterized allogeneic 
MSCs in cartilage disease despite the high interest 
that may raise. Considering there are data indicating a 
potential effect of alloreactivity (Isakova et al., 2014), it 
should be taken into account in current clinical trials.
preclinical studies assessing MsC-based 
therapies for rA
The development of RA therapeutic solutions based 
on MSCs mainly seek to take advantage of their 
immunoregulatory properties in accordance with the 
immunological origin of RA. Nevertheless, cartilage 
repair is still used to assess the beneficial effects. Most 
studies have been conducted in mice in accordance 
with the availability of a well-established RA mouse 
model, the CIA model (Augello et al., 2007; Bouffi et 
al., 2010; Mancheno-Corvo et al., 2017, Park et al., 2017; 
Zhang et al., 2019). Multiple administration routes 
and various sources of MSCs have been studied 
in this setting to develop efficacious therapeutic 
protocols for RA (Table 3). Systemic administration 
routes have been used in the CIA mouse model 
justified by the fact that RA is not only a disease of 
the joints. Early work found a protective effect when 
allogeneic BM-derived MSCs were administered i.p. 
at the time of first immunization (two immunizations 
are conducted in the CIA model separated by 21 d) 
(Augello et al., 2007). However, other teams did not 
observe such protection and found even disease 
exacerbation when injected at later time points 
(Chen et al., 2010). Subsequent work showed that 
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both syngeneic and allogeneic MSCs can display 
immunosuppressive effects and protect from the 
disease when administered in a narrow window 
around the time of the second immunization 
(Bouffi et al., 2010). Nevertheless, this effect is strain 
dependent as allogeneic MSCs from BALB/c mice 
worsen the disease outcome unless the MSCs are 
genetically modified with a tolerogenic molecule 
such as CTLA4-Ig (Sullivan et al., 2013). Human MSC 
preparations have also been tested in the CIA mouse 
model assessing multiple protocols (Mancheno-
Corvo et al., 2017, Park et al., 2017; Zhang et al., 
2019). Intravenous injection of human MSCs from 
various sources (bone marrow, umbilical cord, and 
deciduous teeth), led to therapeutic improvement 
of CIA with various degrees of efficacy depending 
on the tissue of MSC origin (Zhang et al., 2019). 
Interestingly, intra-lymphatic administration of 
human expanded adipose-derived MSCs ameliorated 
CIA and promoted immune regulation (Mancheno-
Corvo et al., 2017). Intraperitoneal injection of human 
bone-marrow-derived MSCs also ameliorated CIA, 
especially when using MSCs genetically engineered 
to express the TNF-blocking drug etanercept (Park 
et al., 2017). Thus, multiple factors affect the outcome 
and point out the need for careful experimental 
design and controls of MSC products prior to clinical 
trials in RA.
 MSC-based studies of RA are very infrequent in 
other species, especially in large animals, impairing 
any comparative analysis. Rats and rabbits have 
been used on rare occasions for RA modeling 
and preclinical assessment of MSC therapeutic 
potential (Table 3) (Liu et al., 2015; Wang et al., 2018). 
Interestingly, Liu et al. (2015) proposed a different 
approach based on implantation of MSCs seeded in 
a fibrin-based gel directly into subchondral defects 
for the repair of RA-induced cartilage injury. Their 
MSC product is not well defined, may be syngeneic 
or allogeneic, but the results are very encouraging 
for counteracting both inflammation and cartilage 
degradation. To the authors’ knowledge, only 
one study was conducted in large animals for this 
purpose (Table 3) (Abdalmula et al., 2017). The work 
by Abdalmula et al. (2017) show good results in 
sheep in a well-designed preclinical study (although 
of short follow up). The study was conducted in 
preparation for clinical trials of an equivalent product 
of human allogeneic MPCs (as named by Mesoblast 
Ltd., Melbourne, Australia) currently being tested in 
clinical trials.
 Work is thus in progress, but it is still of special 
interest to determine whether any or several of these 
animal models of OA or RA can provide relevant 
information that can be translated into clinical trials.
preclinical studies assessing MsC toxicity
The study of possible MSC therapies for cartilage 
repair in non-human primates is highly restricted 
due to its ethical implications and the cost of animal 
housing. Only a selected number of well-designed 
and documented studies in these species are allowed. 
Non-human primates display as the main advantage 
for studying cartilage repair the highest similarity to 
humans at the molecular and physiological levels. 
Therefore, models such as the OA model of the 
cynomolgus macaque can facilitate rapid translation 
into clinical practice when conclusive results are 
obtained. However, its use for MSC research is 
limited to a few studies using mainly autologous 
cells (Kondo et al., 2017; Ohmori et al., 2018) and 
from humans (Fernández-Pernas et al., 2017) in a 
variety of models (Table 2). These models are mainly 
used to assess the safety, toxicity, and feasibility of 
their preparation as a preamble to clinical trials. 
Some studies do not clearly specify the exact origin 
of the MSCs and may be using allogeneic cells or a 
mixture of allogenic and autologous cells (Araki et 
al., 2015; Jiang et al., 2014). Long-term safety of i.a. 
injection of lentiviral-transduced autologous MSCs 
in non-human primates has been recently tested 
by Ohmori et al. (2018) and their migration and 
distribution were assessed when transplanted into 
the striatum of young Macaca fascicularis (Li et al., 
2014). In particular, no toxicity related to stem cell 
transplantation was found in several non-human 
primate studies (Fernández-Pernas et al., 2017; Wang 
et al., 2012). These findings support the use of animals 
genetically close to humans to conduct valuable 
preclinical studies for the development of MSC-based 
therapies for cartilage repair.
Concluding remarks
The preclinical studies currently available show a 
potential therapeutic benefit of MSCs for cartilage 
repair. However, it is clear from both small and 
large animal models that not all protocols and 
conditions lead to amelioration of disease or repair. 
Therefore, it is crucial to optimize the cellular product 
(tissue source, autologous or allogeneic, live cell, 
or exosomes) and administration regimes (dose, 
frequency, route) to achieve therapeutic efficacy. 
Much of this information is being obtained directly 
in clinical trials, but a balance is necessary to avoid 
excessive risk and cost. To this end, rigorous studies 
that compare various options in relevant and well-
established animal models are still needed to help 
set up the bases for additional clinical studies. 
With a good understanding of the limitations of the 
various animal models, careful consideration and 
design of future clinical trials will certainly profit 
from this type of information. Furthermore, it is also 
critical determining the goals and benefits that are 
provided by MSC treatment (cartilage repair versus 
immune regulation) for each targeted indication and 
its comparison to other approaches being currently 
investigated.
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 Numerous preclinical studies are based on 
xenogeneic combinations that assess human MSCs 
in mice, rats, rabbits, or even occasionally in large 
animals. Caution should be taken when trying 
to translate these studies for the development of 
therapeutic solutions based on an allogeneic MSC 
product. Such results are indicative of potential safety 
and efficacy of a product in development but are not 
acceptable for modeling potential xenogeneic clinical 
applications (therapies based on the use of pig or 
bovine MSCs for human patients). Neither could be 
used to provide accurate information regarding the 
allogenicity of the cellular product as this could only 
be attained in humans or in co-culture assays with 
human immune cells. Experiments with allogeneic 
MSCs are scarce in small animal and ovine models 
but are gaining attention in recent years as the field 
progresses towards the clinic. Thus, more studies 
are needed that directly establish the equivalency or 
superiority of this type of MSCs when compared to 
autologous cells.
 In summary, major advances have been made at 
the preclinical level and more studies are expected 
that will need to be validated and later assayed in 
clinical trials to confirm its medical utility. The use of 
large-animal models could be key to attain this goal. 
In parallel, other strategies are emerging that offer 
also great potential and may become complementary 
to the MSC-based therapies such as biomaterial-
guided delivery of gene vectors (Cucchiarini and 
Madry, 2019) and combinatorial strategies of MSCs 
with chondrocytes (Marquina et al., 2017; Nazempour 
and Van Wie, 2016). After all this vast effort on the 
study of MSC-based therapies and the limited clinical 
application currently attained based on efficacy, it is 
justified to set specific goals and program research 
projects that provide clarity on the real therapeutic 
potential of this technology in articular cartilage 
repair.
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discussion with reviewer
stephan Zeiter: Is there a need to have more 
standardized preclinical models?
Authors: Yes. An extensive review of the field 
leads to the understanding that a higher level of 
standardization of some preclinical models would 
help the progress of MSC-based therapies towards 
clinical application. This is especially relevant for 
large animal models that may currently lack the level 
of characterization and tools available in small animal 
models. Nevertheless, large animal models are still 
of high interest because of their greater similarity to 
the human patient. The progress of both preclinical 
and clinical studies should help identifying and 
improving the most informative preclinical models.
editor’s note: The Scientific Editor responsible for 
this paper was Martin Stoddart.
